Drugs / MOMA-341
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06974110 | Jul 2025 → Nov 2027 expected | colorectal cancer, endometrial cancer, gastric cancer, metastatic neoplasm | MOMA Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOMA-341 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06974110 ↗ |
| Route | Oral | “MOMA-341 administered orally” NCT06974110 ↗ |